Studies at KiTZ

Solid and brain tumors

New insights and therapeutic approaches

Brain tumors and other tumors of the central nervous system (CNS) are the second most common cancer in childhood, accounting for about 24 percent of all cases, and are also the most common group of "solid" (i.e., solid, initially spatially limited) tumors.

We always distinguish studies between clinical trials on the one hand, and diagnostic platforms and registry studies on the other. Clinical trials mean that a new treatment is tested for efficacy and tolerability, among other things. Diagnostic platforms offer molecular analyses of tumor material, while registry studies are observational studies that collect data on disease progression.

All of our clinical studies, as well as our diagnostic platforms and registry studies on solid and brain tumors, can be found here for review. We also have an overview of the diagnostic options, which can facilitate sorting.

Clinical Trials

Green indicates studies for which recruitment is still open. Red, on the other hand, are those for which recruitment has been completed. Diagnostic platforms and registry studies follow, as does our overview of diagnostic options.

FIREFLY-1

Pan-RAF inhibitor DAY101 in BRAF-modified, relapsed or progressive LGGs.

All on this study

LOGGIC/FIREFLY-2

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy.

All on this study

INFORM2-NivEnt

Immunotherapy in children and adolescents with refractory high-risk cancers.

All on this study

Larotrectinib (LOXO-101)

Larotrectinib as a TRK inhibitor in children with solid tumors.

All on this study

Abemaciclib

Abemaciclib in children with solid tumors (I3Y-MC-JPCS).

All on this study

Entrectinib

An open-label, dose-escalation, expansion phase I/II study of entrectinib in children with advanced or metastatic solid tumors or primary central nervous system tumors with/or without sufficient treatment options.

All on this study

Selpercatinib

A phase I/II study of the oral RET inhibitor LOXO-292 in pediatric patients with advanced solid or primary central nervous system tumors with alterations in the RET gene.

All on this study

Olaparib

PARP inhibitor olaparib for the treatment of progressive or relapsed solid tumors with alterations in homologous recombination (HRR).

All on this study

Niraparib/ Dostarlimab

Unblinded, multicenter dose-escalation and cohort expansion study of niraparib and dostarlimab in pediatric patients with recurrent or progressive solid tumors (SCOOP).

All on this study

Avapritinib

Phase I/II single-arm study to assess the safety, pharmacokinetics, and antitumor activity of avapritinib in pdiatric patients with tumors dependent on the KIT or PGFRA pathway (BLU-285-3101).

All on this study

Alectinib

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors.

All on this study

Diagnostic options

Which program is suitable for which patient? To provide some clarity here, we have created a flowchart. If you have any questions or need additional information, you can find contact information on the respective program pages.

Diagnostic platforms and registry studies

Here are our diagnostic platforms and registry studies. Clinical trials have been listed above.

INFORM

INdividualized therapy FOr Relapsed Malignancies in Childhood: a unique multi-country genome sequencing program for children with cancer in Europe.

All on this study

MNP Int R

The current MNP Int-R follow-up registry study aims to establish an international registry for the generation and coordination of molecular data in pediatric neuro-oncology.

All on this study

LOGGIC Core

The LOGGIC Core BioClinical database (LOGGIC Core) is a registry of molecular and clinical data for pediatric low-grade gliomas (LGG).

All on this study